Company’s Ovarian Assay is the First in a Series of Planned Indications Using EV3D Technology Platform Optimized for Solid Tumors
GREENVILLE, S.C.– August 1, 2019 – KIYATEC, Inc. today announces that results from its prospective, multi-center pilot study, to investigate their assay’s predictive accuracy and correlation to outcome among newly diagnosed ovarian cancer patients, have been published in Scientific Reports. Study findings represent both a preliminary clinical validation for the company’s ovarian cancer assay and a significant developmental milestone for the assay’s technology platform, known as Ex Vivo 3D Cell Culture (EV3D).
Click HERE to read more.
